Antimycobacterial synergism of clarithromycin and rifabutin

Scandinavian Journal of Infectious Diseases

Volumn 28, Issue 4, 1996, Pages 387-390

  Ghebremichael, Solomon ^a   Svenson, Stefan B ^a   Källenius, Gunilla ^a   Hoffner, Sven E ^a,b  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; RIFABUTIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBACTERIAL ACTIVITY; ARTICLE; ATYPICAL MYCOBACTERIUM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG USE; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; NONHUMAN;

EID: 0029815840     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365549609037925     Document Type: Article

References (23)

1. Heifets LB, Lindholm-Levy PJ, Comstock RD. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis 145: 856-858, 1992.
2. O'Brien RJ, Lyle MA, Snider Jr DE. Rifabutin (Ansamycin LM 427): a rifamycin-S derivative for the treatment of mycobacterial diseases. Rev Infect Dis 9: 519-530, 1987.
3. Heifets LB, Iseman MD, Lindholm-Levy PJ, Kanes W. Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods. Antimicrob Agents Chemother 28: 570-575, 1985.
4. Dautzenberg B, Truffot C, Legris S, Meyohas M-C, Berlie HC, Mercat A, Chevret S, Grosset J. Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. Am Rev Respir Dis 144: 564-569, 1991.
5. Hoy J, Mijch A, Sandland M, Grayson L, Lucas R, Dwyer B. Quadruple-drug therapy for Mycobacterium avium-intracellular bacteremia in AIDS patients. J Infect Dis 161: 801-805, 1990.
6. Iseman MD. Synergism: the rosetta stone for Mycobacterium avium complex chemotherapy. Am Rev Respir Dis 138: 767-768, 1988.
7. Källenius G, Svenson SB, Hoffner SE. Ethambutol: a key for Mycobacterium avium complex chemotherapy? Am Rev Respir Dis 140: 264, 1989
8. Kent PT, Kubica GP. Public health mycobacteriology. A guide for the level III laboratory. Centers for Disease Control, Atlanta, 1985.
9. Hoffner SE. Källenius G, Brennan P, Petrini B, Tsang AY. Serovars of Mycobacterium avium complex isolated from patients in Sweden. J Clin Microbiol 28: 1105-1107, 1990.
10. Middlebrook G, Reggiardo Z, Tigrett WD, Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media. Am Rev Respir Dis 115: 1066-1069, 1977.
11. Hoffner SE, Svenson SB, Källenius G. Synergistic effects of antimycobacterial drugs on Mycobacterium avium complex determined radiometrically in liquid medium. Eur J Clin Microbiol 6: 530-535, 1987.
12. Hoffner SE, Kratz M, Olsson-Liljequist B, Svenson SB, Källenius G. In-vitro synergistic activity between ethambutol and fluorinated quinolones against Mycobacterium avium complex. J Antimicrob Chemother 24: 317-324, 1989.
13. Heifets LB. Dilemmas and realities in drug susceptibility testing of M. avium-M. intracellulare and other slowly growing nontuberculous mycobacteria. In:Drug susceptibility in the chemotherapy of mycobacterial infections, Ed. LB Heifets, CRC Press 1991.
14. Heifets LB. Antituberculous drugs: antimicrobial activity in vitro. In: Drug susceptibility in the chemotherapy of mycobacterial infections, Ed. LB Heifets, CRC Press 1991.
15. Heifets LB, Iseman MD, Lindholm-Levy PJ. Combinations of rifampicin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic and bacteriostatic additive or synergistic effects. Am Rev Respir Dis 137: 711-715, 1988.
16. Hoffner SE, Källenius G, Beezer AE, Svenson SB. Studies on the mechanisms of the synergistic effects of ethambutol and other antibacterial drugs on Mycobacterium avium complex. Acta Leprolog 7(Suppl 1): 195-199, 1989.
17. Yajko DM, Kirihara J, Sanders C, Nassos P, Hadley WK. Antimicrobial synergism against Mycobacterium avium complex strains isolated from patients with acquired immune deficiency syndrome. Antimicrob Agents Chemother 32: 1392-1395, 1988.
18. Perrone C, Gikas A, Truffot-Pernot C, Grosset J, Pocidalo J-J, Vilde J-L. Activities of clarithromycin, sulfisoxazole, and rifabutin against M. avium complex multiplication within human macrophages. Antimicrobial Agents Chemother 34: 1508-1511, 1990
19. Skinner MH, Hsieh M, Torseth J, Pauloin D, Bhatia G, Harkonen S, Merigan TC, Blaschke TF. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother 33: 1237-1241, 1989.
20. Mor N, Heifets LB. MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages. Antimicrob Agents Chemother 37: 111-114, 1993.
21. Mor N, Heifets LB. Inhibition of intracellular growth of Mycobacterium avium by one pulsed exposure of infected macrophages to clarithromycin. Antimicrob Agents Chemother 37: 1380-1382, 1993.
22. Mor N, Vanderkolk J, Heifets LB. Accumulation of clarithromycin in macrophages infected with Mycobacterium avium. Pharmacotherapy 14: 100-104, 1994.
23. Wallace RJ Jr, Brown BA, Griffith DE, Giard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellular infections. J Infect Dis 171: 747-750, 1995.